Vaccinex, Inc. (VCNX)

OTCMKTS · Delayed Price · Currency is USD

1.010

+0.010 (1.00%)

May 5, 2026, 3:11 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
The Discovery and Development of Targeted Biotherapeutics	601.00K	570.00K	275.00K	900.00K	625.00K
The Discovery and Development of Targeted Biotherapeutics Growth	5.44%	107.27%	-69.44%	44.00%	19.50%
Total	601.00K	570.00K	275.00K	900.00K	625.00K
Total Growth	5.44%	107.27%	-69.44%	44.00%	19.50%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	601.00K	570.00K	275.00K	900.00K	625.00K
United States Growth	5.44%	107.27%	-69.44%	44.00%	19.50%
Total	601.00K	570.00K	275.00K	900.00K	625.00K
Total Growth	5.44%	107.27%	-69.44%	44.00%	19.50%

Source: S&P Global Market Intelligence.